GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study (REDUCE PAS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03821129 |
Recruitment Status :
Recruiting
First Posted : January 29, 2019
Last Update Posted : June 7, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stroke PFO - Patent Foramen Ovale | Device: PFO closure with GORE® CARDIOFORM Septal Occluder | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 636 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study |
Actual Study Start Date : | July 25, 2019 |
Estimated Primary Completion Date : | December 2026 |
Estimated Study Completion Date : | December 2029 |
Arm | Intervention/treatment |
---|---|
GORE® CARDIOFORM Septal Occluder
Single Arm Commercially available GORE® CARDIOFORM Septal Occluder
|
Device: PFO closure with GORE® CARDIOFORM Septal Occluder
PFO closure with GORE® CARDIOFORM Septal Occluder in patients with ischemic stroke |
- Proportion of subjects with recurrent ischemic stroke post study device implant (Primary Effectiveness Outcome) [ Time Frame: 24 months ]Proportion of subjects with recurrent ischemic stroke post study device implant
- Proportion of subjects with device- or procedure-related serious adverse events at 30 days (Primary Safety Endpoint) [ Time Frame: 30 days ]Device- or procedure- related serious adverse events post study device implant
- Effective PFO Closure defined as complete PFO closure or a trivial or small residual shunt by Echocardiographic assessment [ Time Frame: 12 months ]
Complete PFO closure or a trivial or small residual shunt
Proportion of subjects with complete PFO closure or a trivial or small residual shunt
- Clinically Significant New Atrial Arrhythmia [ Time Frame: 60 months ]Any new atrial fibrillation or flutter
- Clinically Significant New Atrial Arrhythmia by Age [ Time Frame: 60 months ]Any new atrial fibrillation or flutter in patients greater and less than 60 years of age
- Residual Shunt Characterization via assessment of shunt in patients by Echo [ Time Frame: 24 months ]Assessment of shunt in patients by Echo
- Technical Success defined as successful delivery and retention of the GSO device based on physician reporting [ Time Frame: Index procedure ]Successful delivery and retention of the GSO device
- Procedural Success defined as successful implantation of the GSO device with no reported in-hospital Serious Adverse Events (SAEs) [ Time Frame: Enrollment through discharge, approximately 1 day ]Successful implantation of the GSO device with no reported in-hospital SAEs

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosed with an ischemic stroke presumed to be an embolic stroke of undetermined source (ESUS) verified by a neurologist within the last 365 days prior to enrollment.
- Presence of Patent Foramen Ovale (PFO), as determined initially by positive bubble study utilizing transesophageal echocardiography (TEE) and/or transcranial Doppler (TCD), demonstrating spontaneous right-to-left shunting or right-to-left shunting during Valsalva maneuver.
- Patient is able to tolerate antiplatelet therapy
- Note: Additional Inclusion Criteria may apply
Exclusion Criteria:
- History of or ongoing atrial fibrillation/flutter
- Other co-morbidities including, but not limited to, mural thrombus, dilated cardiomyopathy, cardiac prosthetics (valves), severe native valve disease (including mitral valve stenosis), severe ventricular wall motion abnormalities, aortic dissection, significant atherosclerosis, vasculitis, pre-existing non-vascular neurologic disorders, pulmonary arteriovenous malformations, prior intracranial hemorrhage, severe disability related to prior stroke, autoimmune disorders that would increase the risk of stroke or thromboembolism, or associated with increased risk of infection or procedural complications, in the opinion of the investigator, left ventricular ejection fraction of <40%, coexistent cause or intra-cardiac shunting (e.g. VSD or ASD)
- Previous Myocardial Infarction
- Rankin Scale sore greater than or equal to 3 at the time of procedure
- Active infection that cannot be treated successfully prior to enrollment
- Neurological deficits not due to stroke that may affect the patient's neurologic assessments
- Evidence of hypercoagulable state, Uncontrolled diabetes mellitus, uncontrolled systemic hypertension or pulmonary hypertension at the time of screening or procedure
- Sensitivity or contraindication to all proposed medical treatments or any device components
- Pregnant, lactating, or intent on becoming pregnant through 24 months after enrollment.
- Indications outside the parameters accepted for placement of GSO, including extensive congenital cardiac anomalies and defect diameters considered too large for closure with the device.
- Atrial septal anatomy that is expected to necessitate placement of more than one GORE® CARDIOFORM Septal Occluder
- Need for concomitant procedure(s) that may confound detection of adverse events related to device placement
- Note: Additional Exclusion Criteria may apply

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03821129
Contact: Tammy Delozier | 800-437-8181 | GSO1801@wlgore.com |

Principal Investigator: | Ignacio Inglessis, MD | Interventional Cardiology Associates | |
Principal Investigator: | John Volpi, MD | The Methodist Hospital Research Institute |
Responsible Party: | W.L.Gore & Associates |
ClinicalTrials.gov Identifier: | NCT03821129 |
Other Study ID Numbers: |
GSO 18-01 |
First Posted: | January 29, 2019 Key Record Dates |
Last Update Posted: | June 7, 2022 |
Last Verified: | June 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | Yes |
Occluder Patent Foramen Ovale PFO Stroke Gore Septal Occluder |
Stroke Foramen Ovale, Patent Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases |
Cardiovascular Diseases Heart Septal Defects, Atrial Heart Septal Defects Heart Defects, Congenital Cardiovascular Abnormalities Heart Diseases Congenital Abnormalities |